<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611633</url>
  </required_header>
  <id_info>
    <org_study_id>CHIESI_NIS_004</org_study_id>
    <nct_id>NCT04611633</nct_id>
  </id_info>
  <brief_title>Study in COPD Patients Evaluating the Quality of Life (TRISNOOZE)</brief_title>
  <acronym>TRISNOOZE</acronym>
  <official_title>A Prospective Observational Study in COPD Patients Evaluating the Quality of Life in Patients Switching From a Dual Therapy to a Fixed LABA/LAMA/ICS Triple Therapy in Routine Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi SA/NV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi SA/NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study aims to collect information on the patient's quality of life,&#xD;
      as well as the quality of sleep when stepping up to a fixed triple maintenance therapy&#xD;
      (Trimbow®) as per physicians' decision, independent from study participation, and to assess&#xD;
      its effectiveness in daily life, in general practitioner setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional study assesses the real-life effectiveness, with focus on patient's&#xD;
      quality of life, of the fixed triple therapy Trimbow® after stepping up from a dual therapy&#xD;
      in clinical practice at first line centres in patients with confirmed chronic obstructive&#xD;
      pulmonary disease (COPD). Data will be collected on availability as per usual care at&#xD;
      baseline, 3 and 6 months after inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COPD symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>The patient's COPD symptoms at month 6 (visit 3), compared to baseline. This is measured by the COPD Assessment Test (CAT) questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>The patient's COPD symptoms at month 3 (visit 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sleep</measure>
    <time_frame>6 months</time_frame>
    <description>The quality of sleep of the patients using the CASIS questionnaire at baseline, month 3 and 6 (visit 2 and 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>The patient's treatment satisfaction score using PGI-C at month 3 and 6 (visit 2 and 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>6 months</time_frame>
    <description>Use of rescue medication at baseline and each follow-up visit (question on the past 7 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Lung function parameters (FEV1, FVC) (if available) at baseline and each follow-up visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Moderate/severe exacerbations</measure>
    <time_frame>6 months</time_frame>
    <description>Number of moderate/severe exacerbations at baseline and at month 6</description>
  </other_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Trimbow</intervention_name>
    <description>As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population will include adult patients aged 40 years or above diagnosed with&#xD;
        COPD confirmed by spirometry (Tiffeneau index &lt;0.7), who are stepping up from dual therapy&#xD;
        (ICS/LABA or LABA/LAMA treatment at least 12 weeks prior to enrolment to the study) to a&#xD;
        fixed triple maintenance therapy (Trimbow).&#xD;
&#xD;
        Approximately 800 patients are expected to be enrolled at 200 GP practices in Belgium.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has provided written informed consent&#xD;
&#xD;
          -  Patient is aged 40 years or older&#xD;
&#xD;
          -  Current or ex-smokers with a smoking history ≥ 10 pack years&#xD;
&#xD;
          -  Patient is diagnosed with COPD, confirmed by post-bronchodilator spirometry (Tiffeneau&#xD;
             index &lt;0.7; baseline or older spirometry)&#xD;
&#xD;
          -  Patient is eligible for switch to triple therapy with at least 12 weeks of stable&#xD;
             double inhalation therapy (ICS/LABA or LABA/LAMA) prior to enrolment to the study&#xD;
&#xD;
          -  Patient is starting treatment with Trimbow® upon decision by their physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are hypersensitive to one of the active substances or excipients&#xD;
&#xD;
          -  Patients who are treated with triple therapy (via single or multiple inhalers) in the&#xD;
             last 6 months prior to study enrolment&#xD;
&#xD;
          -  Patients on ICS, LABA or LAMA monotherapy&#xD;
&#xD;
          -  Patients with pneumonia and/or a moderate or severe COPD exacerbation not resolved ≥&#xD;
             14 days prior to screening and ≥ 30 days following the last dose of oral/systemic&#xD;
             corticosteroid (if applicable), or a respiratory tract infection not resolved ≥ 7 days&#xD;
             prior to screening&#xD;
&#xD;
          -  Patients participating simultaneously to other clinical trials or studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Marchand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Godinne UCL Namur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofie Geelissen, PhD</last_name>
    <phone>+3227884231</phone>
    <email>s.geelissen@chiesi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ina Gesquiere, PharmD,PhD</last_name>
    <phone>+3227884222</phone>
    <email>i.gesquiere@chiesi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General practitioners in the province of East Flanders</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Flemish Brabant</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Hainaut</name>
      <address>
        <city>Mons</city>
        <state>Hainaut</state>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Limburg</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Luxembourg</name>
      <address>
        <city>Arlon</city>
        <state>Luxembourg</state>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Walloon Brabant</name>
      <address>
        <city>Wavre</city>
        <state>Walloon Brabant</state>
        <zip>1300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of West Flanders</name>
      <address>
        <city>Bruges</city>
        <state>West Flanders</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Liège</name>
      <address>
        <city>Liège</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-UCL-Namur</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Marchand, MD, PhD</last_name>
      <phone>+32 (0)81 42 33 51</phone>
      <email>eric.marchand@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General practitioners in the province of Namur</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Geelissen, PhD</last_name>
      <phone>+3227884231</phone>
      <email>s.geelissen@chiesi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

